FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+13.35%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.41B
AUM Growth
+$2.41B
(-3.4%)
Cap. Flow
-$42.5M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$78.7M |
| 2 |
Pliant Therapeutics
PLRX
|
$14.8M |
| 3 |
Trevi Therapeutics
TRVI
|
$13.5M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$10.2M |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$7.66M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$41.7M |
| 2 |
Krystal Biotech
KRYS
|
$31.3M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$30.6M |
| 4 |
Vaxcyte
PCVX
|
$27.8M |
| 5 |
Tyra Biosciences
TYRA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rocket Pharmaceuticals
RCKT
$358M
| $18.6M | 0.77% |
1,479,025
-6,605
| -0.4% | -$83K |
|
27
Ascendis Pharma
ASND
$12.1B
| $18.4M | 0.76% |
133,333
| – | – |
|
|
MREO
28
Mereo BioPharma
MREO
$275M
| $17.8M | 0.74% |
5,097,779
| – | – |
|
29
Alkermes
ALKS
$4.95B
| $17.3M | 0.72% |
601,129
+25,000
| +4% | +$719K |
|
30
Merus
MRUS
$5.04B
| $15.7M | 0.65% |
373,100
| – | – |
|
31
Immatics
IMTX
$662M
| $15.3M | 0.63% |
2,147,911
+793,200
| +59% | +$5.64M |
|
|
32
Pliant Therapeutics
PLRX
$105M
| $14.8M | 0.61% |
+1,120,803
| New | +$14.8M |
|
33
Design Therapeutics
DSGN
$339M
| $12.1M | 0.5% |
1,953,547
+61,000
| +3% | +$376K |
|
|
ORKA
34
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $11.3M | 0.47% |
583,327
+106,000
| +22% | +$2.06M |
|
|
AUTL
35
Autolus Therapeutics
AUTL
$383M
| $10.9M | 0.45% |
4,623,324
| – | – |
|
36
MacroGenics
MGNX
$121M
| $10.3M | 0.43% |
3,175,665
+164,938
| +5% | +$536K |
|
37
Day One Biopharmaceuticals
DAWN
$766M
| $8.74M | 0.36% |
689,655
| – | – |
|
38
Acadia Pharmaceuticals
ACAD
$4.34B
| $8.63M | 0.36% |
470,338
| – | – |
|
|
SLN
39
Silence Therapeutics
SLN
$237M
| $7.9M | 0.33% |
1,148,591
| – | – |
|
|
PVLA
40
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $7.85M | 0.33% |
653,892
+637,950
| +4,002% | +$7.66M |
|
41
89bio
ETNB
$1.37B
| $7.82M | 0.32% |
1,000,000
| – | – |
|
42
Cogent Biosciences
COGT
$1.83B
| $7.31M | 0.3% |
936,576
| – | – |
|
|
43
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$64M
| $7.13M | 0.3% |
500,333
| – | – |
|
44
Lexeo Therapeutics
LXEO
$266M
| $6.29M | 0.26% |
955,515
-295,271
| -24% | -$1.94M |
|
45
Allogene Therapeutics
ALLO
$249M
| $6.11M | 0.25% |
2,867,750
| – | – |
|
46
Arvinas
ARVN
$580M
| $5.47M | 0.23% |
285,331
| – | – |
|
47
Adverum Biotechnologies
ADVM
$68.2M
| $4.99M | 0.21% |
1,069,244
| – | – |
|
48
Eledon Pharmaceuticals
ELDN
$155M
| $4.85M | 0.2% |
+1,176,735
| New | +$4.85M |
|
|
ELEV
49
DELISTED
Elevation Oncology
ELEV
| $3.37M | 0.14% |
5,993,579
| – | – |
|
50
Immunocore
IMCR
$1.78B
| $3.21M | 0.13% |
108,762
| – | – |
|